share_log

Scotiabank Initiates Coverage On INmune Bio With Sector Outperform Rating, Announces Price Target of $22

Benzinga ·  Aug 22 20:32  · Ratings

Scotiabank analyst George Farmer initiates coverage on INmune Bio (NASDAQ:INMB) with a Sector Outperform rating and announces Price Target of $22.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment